Abstract

This first clinical prospective study was conducted to use of technetium-99m immunoglobulin G (99mTc-IgG) as compared with autologous 99mTc-red blood cells (RBC) in gated blood pool ventriculography. We studied 12 patients who referred to us for a possible diagnosis of liver hemangioma or infection. Six patients underwent gated planar blood pool (GPBP) acquisition using 99mTc-RBC and 6 GPBP acquisition using 99mTc-IgG. The use of 99mTc-IgG in cardiac blood pool studies provided comparable images to 99mTc-RBC. In conclusion, 99mTc-IgG, which is readily available and needs only a single injection, may be an attractive alternative to 99mTc-RBC for the estimation of various cardiac function parameters like left ventricular function.

Introduction

Left ventricular (LV) function and ejection fraction (EF) studied by radionuclidic echocardiographic techniques have long been diagnostic factors associated with cardiac function [1-3]. However, echocardiographic investigations (ECHOC) may have poor reproducibility and be unable to diagnose some lesions like those in the endocardium and the apex [4, 5] and gated single photon emission tomography (GSPECT) perfusion studies may be difficult to identify lesions with marked hypoperfusion [6].

Gated blood pool ventriculography (GBPV) is usually carried out by labeling autologous red blood cells (RBC) with 99mTc-RBC [7]. Practical drawbacks of the 99mTc-RBC technique time and labor and the necessary manipulations of blood samples with a possible risk of contamination [8]. A number of studies have tried to use other blood-pool agents in addition to 99mTc-RBC [9-13].

This article presents the first clinical prospective study using 99mTc-gamma immunoglobulin (IgG) as compared with 99mTc-RBC in GBPV, by measuring organ activity ratios and image quality.

Patients and methods

The study population included 12 patients (7 men and 5 women mean age 59.92±8.07 years) who had been referred to us for possible diagnosis of liver hemangioma or infection (Table 1). None had symptoms of typical or atypical ischemic heart disease (IHD) such as chest pain, history of myocardial infarction (MI), congestive heart failure, arrhythmia or history of coronary interventions such as catheterization or coronary angioplasty.

Six patients underwent GBPV acquisition using 99mTc-RBC (Fig. 1), and the remaining six cases underwent GBPV with 99mTc-IgG (Fig. 2).

This study complied with the declaration of Helsinki and was approved by the Institutional Ethics Committee of Golestan University of Medical Science. All patients signed a written fully informed consent.

Technetium-99m-RBC labeling was carried out using a modified in vitro method (ex-vivo) [10, 14]. The radiopharmaceutical was administered by direct intravenous (i.v.) injection [15]. According to this technique, at least 10min after stannous chloride administration (0.5mg to 2mg), 2-3mL of blood is withdrawn from the subject into a containing 99mTcO₄⁻ syringe, and then administered using separate venous access to that used for the stannous chloride administration previously. More than 95% labeling efficiency was achieved by this direct technique. For 99mTc-IgG preparation, a human nonspecific polyclonal IgG solution.
with a concentration of about 10mg/mL in 0.01 M phosphate buffered saline (PBS) of pH 7.4 was acquired. Protein concentration was appraised by Lowry technique [16]. The IgG was reduced by reacting with a molar excess of 2-mecaptopropanol 2000:1 (2-ME:IgG) and was incubated for 30min at room temperature. The reduced solution was then purified by eluting through a 1×15cm sephadex G25 column, using nitrogen purged phosphate buffered saline (PBS) as mobile phase. Aliquots containing 1mg of reduced protein and 20μL of previously reconstituted solution with 5mL of saline were mixed, passed through a 0.22μ membrane filter and then frozen in −80 °C. The reduced products were lyophilized for 48h, sealed under vacuum, and stored at 4 °C until use. For 99mTc labeling, vials of lyophilized reduced IgG were reconstituted with 740MBq of 99mTcO4 eluted from a 99Mo/99mTc generator (Atomic Energy Organization of Iran, Tehran, Iran) [16]. The total cost of each compound was approximately $60.

Gated BPV images were obtained and processed with commercially available software. For LVEF assessment, an observer (H.J) delineated the initial LV contours at end systole (ES) and end diastole (ED).

Background (bg) region of interest (ROI) were also acquired by use of a 2 to 3 pixel-wide crescent-shaped region located about 2 pixels far from the posterolateral wall. After the subtraction of a bg region surrounding the LV, EF was calculated by following formula:

\[ EF(\%) = \frac{|ED \text{ counts} - ES \text{ counts}|}{ED \text{ counts}} \times 100. \]

In addition, activities within the aforementioned bg region and the ED image of the LV were calculated and expressed in counts per pixel (c/p) to determine the LV/bg ratio.

In order to evaluate the activity ratios in different organs, regions of interest (ROI) were manually drawn over the LV, right ventricle (RV), right lung, left lung, aorta, liver, and spleen on the static anterior datasets at 20min (early) and at 180min (delayed) post injection of 99mTc-RBC (Fig. 1) and of 99mTc-IgG (Fig. 2). These ROI also were expressed in c/p. The c/p ratios between early and delayed views were compared for each ROI.

Image quality was also blindly assessed by two observers (M.M. and M.A.) using as criteria the simplicity of outlining the ED and ES, LV edges. Quality was classified as good, mild, or poor for both radiotracers. The data were expressed as mean±standard deviation (±SD); the Mann–Whitney U test was applied for quantitative comparison, and differences in proportion (categorical variables) were assessed by the chi-square test. A P value of <0.05 was considered statistically significant.

## Results

None of the patients had any adverse reactions such as nausea, flushing, coughing, dyspnea, muscle cramps or dizziness after the i.v. injection of 99mTc-IgG. The mean acquisition times following injection of each radiotracer are shown in Table 1. Observers 1 and 2 based upon image qualities considered both radiotracers as of good quality for all participants. The demographic data and GBPV parameters including mean count/frame, EF, peak filling rate–end diastolic volume per second(PFR-EDV/S), peak filling rate (PFR), peak emptying rate (PFR)– EDV/sec, PER and LV/BKG between the two groups were not statistically different (Table 1).

A contrast analysis of both compounds was carried out in terms of organ c/p ratios between early and delayed images. The mean c/p of the LV and the RV to the bg ratios on early and delayed views in patients with 99mTc-IgG were greater, relative to patients who had been tested with radiolabeled 99mTc-RBC (Table 2). The ten (as shown in Table 2) ratios in the early and delayed views between the two radiotracers were not significantly different (P value>0.05).

In addition, organ ROI c/p was compared with respect to the biodistribution of the two radiopharmaceuticals over time by subtracting ROI c/p of early acquired, from delayed ROI of the static images. This comparison showed that the washout rate of 99mTc-IgG relative to 99mTc-RBC was not significantly different (Fig. 3).

### Table 1. The main characteristics and results of the two groups studied

<table>
<thead>
<tr>
<th>Radiopharmaceutical</th>
<th>99mTc-RBC</th>
<th>99mTc-IgG</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (year)</td>
<td>62.00±8.87</td>
<td>57.83±7.36</td>
<td>0.37</td>
</tr>
<tr>
<td>Male/Female</td>
<td>4/2</td>
<td>3/3</td>
<td>0.55</td>
</tr>
<tr>
<td>Post injection time</td>
<td>75.83±11.75</td>
<td>80.00±7.09</td>
<td>0.63</td>
</tr>
<tr>
<td>Mean count/frame</td>
<td>326.50±187.30</td>
<td>424.17±239.81</td>
<td>0.42</td>
</tr>
<tr>
<td>EF (%)</td>
<td>59.00±7.64</td>
<td>58.33±16.03</td>
<td>0.52</td>
</tr>
<tr>
<td>PFR-EDV/S</td>
<td>3.20±0.77</td>
<td>2.49±0.62</td>
<td>0.15</td>
</tr>
<tr>
<td>PFR (ms)</td>
<td>459.50±39.09</td>
<td>491.33±49.84</td>
<td>0.15</td>
</tr>
<tr>
<td>PER-EDV/S</td>
<td>-3.02±0.51</td>
<td>-2.62±0.74</td>
<td>0.15</td>
</tr>
<tr>
<td>PER(ms)</td>
<td>97.00±20.74</td>
<td>112.00±21.53</td>
<td>0.15</td>
</tr>
<tr>
<td>LV/BKG</td>
<td>2.55±0.99</td>
<td>2.11±0.78</td>
<td>0.52</td>
</tr>
</tbody>
</table>

EF, ejection fraction; PFR-EDV/S, peak filling rate–end diastolic volume per second; PFR (ms), peak filling rate in millisecond; PER-EDV/S, peak emptying rate–end diastolic volume second; PER(ms), peak emptying rate in millisecond; LV/BKG, left ventricle/bg.
**Discussion**

Despite the advantages of planar GBPV, there are limitations, such as operator-dependent variability in determining the best septal view and underestimation of the LVEF in anterior and inferior myocardial infarction, which are overcome by the SPET mode [17, 18].

The LV and RV activity divided to bg did not differ between the two agents, so the blood pool images with $^{99m}$Tc-IgG may be adequate for clinical application.

Other $^{99m}$Tc-labeled agents, such as human serum albumin ($^{99m}$Tc-HSA) [10], diethylen triamine penta acetate-human serum albumin (DTPA-HSA) [11], and bis diethylphosphonoethane bis-t-butylisocyanide ($^{99m}$Tc-DEPIC) [13] have been used in GBPV acquisition [10, 11, 13]. As for these techniques, because of the rather weak binding of the radionuclide to the protein and the resulting fast extravascular diffusion [11], labeled RBC remain the radiopharmaceutical in routine practice [19].

Our work showed that $^{99m}$Tc-IgG had a better washout rate from blood pools and background regions than $^{99m}$Tc-RBC when used for cardiac blood-pool imaging [18]. Such an increased washout rate does not reduce effective tracer activity and the target-to-background ratios. Although we did not document the washout rate directly by obtaining sequential blood samples, the heart-to-background ratios of the two radiopharmaceuticals was an indicator for this finding.

Our findings may indicate that $^{99m}$Tc-IgG is a promising agent for GBPV having a stable biodistribution and providing good image quality up to 3h post injection. Even on the delayed study, a good contrast between the LV and the surrounding organs was acquired, permitting a precise calculation of the EF value. We were unable to find a similar study in the literature. Further studies with more cases are needed to confirm these findings.

Our work showed that $^{99m}$Tc-IgG had a better washout rate from blood pools and background regions than $^{99m}$Tc-RBC when used for cardiac blood-pool imaging [18]. Such an increased washout rate does not reduce effective tracer activity and the target-to-background ratios. Although we did not document the washout rate directly by obtaining sequential blood samples, the heart-to-background ratios of the two radiopharmaceuticals was an indicator for this finding.

Our findings may indicate that $^{99m}$Tc-IgG is a promising agent for GBPV having a stable biodistribution and providing good image quality up to 3h post injection. Even on the delayed study, a good contrast between the LV and the surrounding organs was acquired, permitting a precise calculation of the EF value. We were unable to find a similar study in the literature. Further studies with more cases are needed to confirm these findings.

In conclusion, our results showed that the use of $^{99m}$Tc-IgG in cardiac blood pool studies might be an alternative to $^{99m}$Tc-RBC for the measurement of LV and EF function.

All authors declare that they have no conflicts of interest.
Bibliography


